Vivani Medical jumps as Novo Nordisk evaluates weight-loss drug implant

Vivani Medical

07/07/2026 12:55

** Shares of Vivani Medical VANI.O soars 19% to $1.55 premarket
** The biotech firm says it signed an agreement allowing Novo Nordisk to evaluate its experimental weight-loss drug implant
** NPM-139 is designed to provide long-lasting delivery of obesity medicines through an implant, potentially reducing the need for frequent injections - VANI
** The deal includes no exclusivity rights for Novo Nordisk
** Co expects to begin an early-stage human study in mid-2026, comparing the implant with Novo Nordisk's Wegovy obesity injections
** Study will assess safety and how the drug moves through the body, with the aim of advancing to a larger trial if results are positive
** As of last close, stock was up ~6% YTD
 
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))